Develops and markets new drugs that address critical unmet medical needs in the areas of cancer, mens and womens health, skin diseases, osteoporosis, and metabolic, cardiovascular and inflammatory diseases.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Ligand has a number of good partnerships with strong pharma companies and they seem to have several good products in the pipeline. Buzz is about that Ligand is a potential target for acquisition but that's just hearsay; nevertheless, I think they could do quite well. Lots of inside ownership. I'll wait until the May 6 conference call and then make a purchasing decision.
Clarifying, there seem to be a lot of suboptimal financial numbers...hence waiting until the 5/6 conference call.